ABSTRACT
With data from 2 US claims databases (Optum, CVS Health) supplemented with Immunization Information System COVID-19 vaccine records, we evaluated overall and time-specific vaccine effectiveness (VE) of an initial primary series for 3 monovalent COVID-19 vaccines—BNT162b2, mRNA-1273, and JNJ-7836735—in adults (18-64 years). Vaccinated individuals were matched to unvaccinated comparators, and we estimated VE against any medically diagnosed COVID-19 and hospital/emergency department (ED)-diagnosed COVID-19. Additionally, we estimated VE by era of predominant variants, in subgroups, and compared across vaccine brands. The cohorts consisted of 341,097 (Optum) and 1,151,775 (CVS Health) matched pairs for BNT162b2; 201,604 (Optum) and 651,545 (CVS Health) for mRNA-1273; and 49,285 (Optum) and 149,813 (CVS Health) for JNJ-7836735. Summary VE estimates from meta-analysis against hospital/ED-diagnosed COVID-19 were: BNT162b2, 77% (95% CI, 76%-78%); mRNA-1273, 84% (95% CI, 83%-85%), JNJ-7836735 66% (95% CI, 63%-68%). VE estimates were higher for hospital/ED-diagnosed COVID-19 than for medically diagnosed COVID-19, and VE estimates were highest in adults receiving mRNA-1273 for both outcomes. VE was sustained for approximately 7 months for medically-diagnosed and up to 9 months for hospital/ED-diagnosed COVID-19. VE differed by brand and variant era. Additional real-world research is needed as new variants and recommendations for updated vaccines have evolved.
Competing Interest Statement
This work was supported by the United States Food and Drug Administration as part of the BEST Initiative. JBL, CB, DI, MMR, and MSA are employees of RTI International, an independent, nonprofit research institute that performs research on behalf of governmental and commercial clients, including vaccine manufacturers. LP, JD, RO, RP, MM, JS, LBW, GWY, JS, and KA are employees of Optum and own stock in UnitedHealth Group. EJB is an employee of Optum. DAD and CNMW are employees of CVS Health. The other authors have no conflicts to report.
Clinical Protocols
https://bestinitiative.org/wp-content/uploads/2022/03/C19-VX-Effectiveness-Protocol_2022_508.pdf
Funding Statement
This work was supported by the United States Food and Drug Administration as part of the BEST Initiative.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This activity was conducted as part of the FDA public health surveillance mandate, and FDA did not require Institutional Review Board review.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* Affiliation at time of study
Data Availability
The data that support the findings of this study are available from Optum and CVS Health. Restrictions apply to the availability of these data which were authorized for use in this study.
Abbreviations
- CI
- confidence interval
- COVID-19
- coronavirus disease 2019
- ED
- emergency department
- HR
- hazard ratio
- IIS
- Immunization Information Systems
- Q1, Q3
- first and third quartiles
- QBA
- quantitative bias analysis
- RR
- risk ratio
- RVE
- relative vaccine effectiveness
- SD
- standard deviation
- sIPT
- stabilized inverse probability of treatment
- US
- United States
- VE
- vaccine effectiveness.
